SPDR S&P Biotech ETF (XBI) Shares Sold by Certified Advisory Corp

Share on StockTwits

Certified Advisory Corp trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 17.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,445 shares of the exchange traded fund’s stock after selling 305 shares during the quarter. Certified Advisory Corp’s holdings in SPDR S&P Biotech ETF were worth $104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of XBI. Truewealth LLC acquired a new stake in SPDR S&P Biotech ETF during the 4th quarter worth about $29,000. Essex Savings Bank acquired a new position in SPDR S&P Biotech ETF in the fourth quarter worth approximately $120,000. Private Ocean LLC increased its holdings in SPDR S&P Biotech ETF by 73.7% in the fourth quarter. Private Ocean LLC now owns 1,761 shares of the exchange traded fund’s stock worth $126,000 after buying an additional 747 shares during the last quarter. Rehmann Capital Advisory Group increased its holdings in SPDR S&P Biotech ETF by 33.0% in the third quarter. Rehmann Capital Advisory Group now owns 1,435 shares of the exchange traded fund’s stock worth $138,000 after buying an additional 356 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in SPDR S&P Biotech ETF in the third quarter worth approximately $153,000.

Shares of SPDR S&P Biotech ETF stock opened at $82.68 on Monday. SPDR S&P Biotech ETF has a 12-month low of $64.38 and a 12-month high of $101.55.

WARNING: “SPDR S&P Biotech ETF (XBI) Shares Sold by Certified Advisory Corp” was first posted by Zolmax and is owned by of Zolmax. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://zolmax.com/investing/spdr-sp-biotech-etf-xbi-shares-sold-by-certified-advisory-corp/2890905.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MustangCoin  Price Hits $0.0138 on Top Exchanges
MustangCoin Price Hits $0.0138 on Top Exchanges
Tokenomy  Price Tops $0.0483 on Major Exchanges
Tokenomy Price Tops $0.0483 on Major Exchanges
Cantor Fitzgerald Reaffirms Hold Rating for Gartner
Cantor Fitzgerald Reaffirms Hold Rating for Gartner
AXMIN  Reaches New 1-Year High at $0.37
AXMIN Reaches New 1-Year High at $0.37
QinetiQ Group  Reaches New 12-Month High at $311.50
QinetiQ Group Reaches New 12-Month High at $311.50
Gentex Co.  Position Lifted by Stevens Capital Management LP
Gentex Co. Position Lifted by Stevens Capital Management LP


Leave a Reply

 
© 2006-2019 Zolmax.